Mumbai, Oct 3: Wockhardt, a leading Indian pharmaceutical company, has achieved a major breakthrough with the development of Zaynich, a new antibiotic targeting multi-drug-resistant (MDR) Gram-negative bacteria that resist existing treatments. The drug combines cefepime and zidebactam, offering a potent new option against dangerous pathogens such as E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter species.

Bacterial drug resistance has become a global health emergency, as infections increasingly fail to respond to available antibiotics. Zaynich represents a significant advancement for India and the international medical community in combating this critical problem.

Challenges of Drug Resistance

Gram-negative bacteria pose a major challenge due to their complex c

See Full Page